Khan, K. 2025. Efficacy and safety of sitagliptin, metformin and pioglitazone fixed-dose combination therapy (100 mg/1000mg and 15 mg respectively) as a first-line treatment in obese type 2 diabetes with high insulin resistance. International Journal of Medical and Biomedical Studies. 9, 1 (Feb. 2025), 247–251. DOI:https://doi.org/10.32553/ijmbs.v9i1.3064.